ProCE Banner Activity

Respondendo a perguntas-chave sobre o tratamento ideal para doentes com leucemia linfocítica crónica recaída/refratária

Clinical Thought

Nesta atividade, os especialistas abordam questões-chave relativas ao cuidado de doentes com leucemia linfocítica crónica (LLC) recaída/refratária (R/R), conforme discutido durante um webinar ao vivo do tipo mesa redonda. Essas respostas fornecem informações práticas e aplicáveis que os profissionais de saúde (HCPs) podem usar na clínica. 

Released: December 23, 2024

Expiration: December 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Othman Al-Sawaf, MD

Department of Hematology and Oncology
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

Alessandra Tedeschi, MD

Medical Doctor
Department of Hematology
Niguarda Cancer Center Milano
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson.